{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:25Z","timestamp":1791994585140,"version":"4.4.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073429, 82273510, 82003335"],"award-info":[{"award-number":["82073429, 82273510, 82003335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["2019-01-07-00-07-E00046"],"award-info":[{"award-number":["2019-01-07-00-07-E00046"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR1014B"],"award-info":[{"award-number":["SHDC2020CR1014B"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["20XD1403300"],"award-info":[{"award-number":["20XD1403300"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for AIBD involves the use of glucocorticoids or traditional immunosuppressants. Additionally, the utilization of biological agents such as rituximab, omalizumab, and dupilumab is on the rise. However, effectively managing AIBD remains a challenge. The Janus kinase\/signal transducers and activators of transcription (JAK\/STAT) pathway has been implicated in various inflammatory diseases. In recent years, a range of drugs known as JAK inhibitors, which target this pathway, have been developed. Several studies have explored the efficacy and safety of JAK inhibitors for treating AIBD. Consequently, this review begins by examining the role of the JAK\/STAT pathway in AIBD, summarizing the application of different JAK inhibitors in AIBD treatment, and emphasizing the importance of disease management in treating AIBD with JAK inhibitors. Furthermore, it highlights the need for a better understanding of the JAK\/STAT pathway\u2019s role in AIBD, as well as the effectiveness and safety of JAK inhibitors for treating this disease.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1220887","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T08:18:29Z","timestamp":1688977109000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Janus kinase inhibitors in autoimmune bullous diseases"],"prefix":"10.3389","volume":"14","author":[{"given":"Dawei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011","article-title":"Mortality of bullous pemphigoid in switzerland: a prospective study","volume":"165","author":"Cort\u00e9s","year":"2011","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.058","article-title":"Bullous pemphigoid: rituximab to the rescue","volume":"82","author":"Heymann","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1788702","article-title":"Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients","volume":"33","author":"Kianfar","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/dth.12327","article-title":"Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus","volume":"29","author":"Tavakolpour","year":"2016","journal-title":"Dermatol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":":2002","DOI":"10.3390\/cancers11122002","article-title":"Jak-stat signaling: a double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - a network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489","article-title":"Jak inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of janus kinase (jak) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1701","article-title":"Selectivity and therapeutic inhibition of kinases: to be or not to be","volume":"10","author":"Ghoreschi","year":"2009","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The jak-stat pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12026-020-09122-y","article-title":"Expression of jak3, stat2, stat4, and stat6 in pemphigus vulgaris","volume":"68","author":"Juczynska","year":"2020","journal-title":"Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15249","article-title":"Multiple cycles of rituximab therapy for pemphigus: a group of patients with difficult- to-treat disease or a consequence of late rituximab initiation","volume":"35","author":"Balighi","year":"2022","journal-title":"Dermatol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.4.438","article-title":"Analysis of serum cytokine profile in pemphigus","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.1.635","article-title":"Dichotomy of autoreactive th1 and th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (pv) and healthy carriers of pv-associated hla class ii alleles","volume":"170","author":"Veldman","year":"2003","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nri2735","article-title":"How are t(h)2-type immune responses initiated and amplified","volume":"10","author":"Paul","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the jak\/stat signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1515","article-title":"Identification of immunodominant th2-cell epitopes in chinese patients with bullous pemphigoid","volume":"138","author":"Zhang","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/205873929901200202","article-title":"A th2-like cytokine response is involved in bullous pemphigoid. the role of il-4 and il-5 in the pathogenesis of the disease","volume":"12","author":"Feliciani","year":"1999","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced il-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"Jak selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.014","article-title":"From empirical to pathogenesis-based treatments for psoriasis","volume":"142","author":"van de Kerkhof","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128154","article-title":"The cytokine milieu of bullous pemphigoid: current and novel therapeutic targets","volume":"10","author":"Maglie","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00520-4","article-title":"Eosinophilic dermatoses: recognition and management","volume":"21","author":"Marzano","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdermsci.2014.11.003","article-title":"Regulatory t cells as well as il-10 are reduced in the skin of patients with dermatitis herpetiformis","volume":"77","author":"Antiga","year":"2015","journal-title":"J Dermatol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5965492","article-title":"The role of intereukin-31 in pathogenesis of itch and its intensity in a course of bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Kulczycka-Siennicka","year":"2017","journal-title":"BioMed Res Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1084","article-title":"Effects of il-4 on conjunctival fibroblasts: possible role in ocular cicatricial pemphigoid","volume":"44","author":"Razzaque","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090579","article-title":"Conjunctival interleukin-13 expression in mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro","volume":"175","author":"Saw","year":"2009","journal-title":"Am J Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-9322","article-title":"Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients","volume":"53","author":"Suelves","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14789","article-title":"Elevation of serum interleukin-21 in patients with epidermolysis bullosa acquisita","volume":"46","author":"Park","year":"2019","journal-title":"J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169947","article-title":"Mouse models of pemphigus: valuable tools to investigate pathomechanisms and novel therapeutic interventions","volume":"14","author":"Emtenani","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.865241","article-title":"Cutaneous kinase activity correlates with treatment outcomes following pi3k delta inhibition in mice with experimental pemphigoid diseases","volume":"13","author":"Ghorbanalipoor","year":"2022","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/vde.12949","article-title":"Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus","volume":"32","author":"Carrasco","year":"2021","journal-title":"Vet Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/vde.12458","article-title":"A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib","volume":"28","author":"Aymeric","year":"2017","journal-title":"Vet Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.07.013","article-title":"Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate","volume":"27","author":"Burningham","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with janus kinase inhibitor baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15344","article-title":"Effective treatment of refractory lichen planus pemphigoides with a janus kinase-1\/2 inhibitor","volume":"47","author":"Moussa","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":":eaav7561","DOI":"10.1126\/scitranslmed.aav7561","article-title":"Ifn-\u03b3 enhances cell-mediated cytotoxicity against keratinocytes via jak2\/stat1 in lichen planus","volume":"11","author":"Shao","year":"2019","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3174","article-title":"Epidermolysis Bullosa Pruriginosa Treated with Baricitinib","volume":"157","author":"Jiang","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S182891","article-title":"Profile of tofacitinib in the treatment of ulcerative colitis: an evidence-based review of recent data","volume":"13","author":"Varyani","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The jak inhibitor, tofacitinib, reduces the t cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":":6","DOI":"10.5070\/D327754365","article-title":"Significant improvement of dermatitis herpetiformis with tofacitinib","volume":"27","author":"Kahn","year":"2021","journal-title":"Dermatol Online J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101104","article-title":"Tofacitinib for refractory ocular mucous membrane pemphigoid","volume":"22","author":"James","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6250","article-title":"Treatment of recurrent epidermolysis bullosa acquisita with tofacitinib","volume":"159","author":"Fan","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2022.10.028","article-title":"Two cases of bullous pemphigoid effectively treated with oral tofacitinib","volume":"32","author":"Youssef","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1159\/000525462","article-title":"Nail loss in mild to moderate pemphigus vulgaris","volume":"8","author":"Vander","year":"2022","journal-title":"Skin Appendage Disord"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac078","article-title":"Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases","volume":"188","author":"Fan","year":"2023","journal-title":"Br J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: a possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/ced.14998","article-title":"Successful use of tofacitinib in epidermolysis bullosa pruriginosa","volume":"47","author":"Chen","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.668825","article-title":"Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cgvhd after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"v732","DOI":"10.2340\/actadv.v102.1378","article-title":"Ruxolitinib, a jak1\/2 inhibitor as treatment for paraneoplastic pemphigus: a case report","volume":"102","author":"Fan","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2050313X","DOI":"10.1177\/2050313X231160926","article-title":"A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: a case report","volume":"11","author":"Gresham","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18487","article-title":"Epidermolysis bullosa pruriginosa with extensive truncal involvement treated with upadacitinib","volume":"37","author":"Kim","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and jak inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of fda-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2039630","article-title":"Safety of jak inhibitors: focus on cardiovascular and thromboembolic events","volume":"18","author":"Atzeni","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","article-title":"Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials","volume":"22","author":"King","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from oral surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2023.2194631","article-title":"Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Shehab","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"kead211","DOI":"10.1093\/rheumatology\/kead211","article-title":"Venous and arterial thromboembolic risk of jak inhibitors: a systematic review with meta-analysis","author":"Campanaro","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"ard-2023-223916","DOI":"10.1136\/ard-2023-223916","article-title":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the select phase iii rheumatoid arthritis clinical programme","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200866","article-title":"Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 jak1 atopic dermatitis efficacy and safety (jade) regimen clinical trial","volume":"34","author":"Flohr","year":"2023","journal-title":"J Dermatol Treat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1220887\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T08:18:35Z","timestamp":1688977115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1220887\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2023.1220887"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1220887","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"article-number":"1220887"}}